Urologists face a significant risk of on-the-job pain and injury, an exclusive Urology Times survey has found.
Vol. 47 No. 8
The treatment provides an alternative to simple prostatectomy in men with large prostates.
Injury stemming from awkward maneuvers and equipment can and should be prevented, says Henry Rosevear, MD.
Results of a phase III trial show the benefit of darolutamide (Nubeqa) in reducing the risk of metastases or death compared with placebo in men with nonmetastatic castration-resistant prostate cancer.
Work out decisions on combined accounts and long-term goals before the big day, advises Jeff Witz, CFP.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC
5
